• In early May 2026, Healthpeak Properties, Inc. reported first-quarter 2026 results showing higher revenue of US$752.95 million and net income of US$193.63 million, and raised its full-year 2026 diluted EPS guidance to US$0.46–US$0.50.
• The stronger outlook was underpinned by the Janus Living IPO, which generated about US$880 million while leaving Healthpeak with an 81.6% stake, alongside senior housing acquisitions, a Blackstone joint venture, and share repurchases.
• Next, we’ll examine how the raised 2026 earnings guidance, supported by the Janus Living IPO, reshapes Healthpeak’s existing investment narrative.

Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

Healthpeak Properties Investment Narrative Recap

To own Healthpeak today, you need to believe in steady demand for outpatient medical and senior housing assets, supported by disciplined capital allocation. The key near term catalyst is whether the Janus Living IPO and related transactions translate into cleaner earnings and better balance sheet flexibility, while the biggest current risk remains exposure to capital markets volatility and tenant credit, especially in labs. The latest guidance upgrade reinforces the story but does not eliminate those risks.

The raised 2026 diluted EPS guidance to US$0.46–US$0.50, coming alongside first quarter net income of US$193.63 million, is the most relevant update here. It sits alongside the Janus Living IPO proceeds of about US$880 million, the Blackstone joint venture on outpatient medical assets, and ongoing share repurchases, all of which feed directly into the same capital recycling and earnings quality themes that underpin the near term catalyst.

Yet investors should also be aware that if capital markets stay volatile and refinancing costs keep rising, Healthpeak’s room to keep recycling assets and funding growth could...

Healthpeak Properties' narrative projects $3.1 billion revenue and $198.8 million earnings by 2028. This requires 3.0% yearly revenue growth and about a $34.8 million earnings increase from $164.0 million today.

Uncover how Healthpeak Properties' forecasts yield a $20.17 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$3.2 billion and earnings about US$285 million by 2029, while also counting on AI driven margin gains; that is a much more optimistic story than the baseline view, and you should expect those forecasts and the interest rate risk around them to be rethought as fresh results like this come through.

Explore 5 other fair value estimates on Healthpeak Properties - why the stock might be worth 19% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Healthpeak Properties research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Healthpeak Properties research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Healthpeak Properties' overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.